BefejeződöttFázis nélkül
Comparison of Two Pulmonary Embolism Treatments
A legfontosabb adatok
- Ki végzi
- Penumbra Inc.
- Hol
- Austin, Baltimore, Bay City, Camden, Chicago, Dallas, Decatur, Edgewood, Kingwood, Lakeland, Los Angeles, Marietta, New York, Norfolk, Royal Oak, San Antonio és Tucson (Egyesült Államok)Mind a 19 helyszín megnézéseMég 3 másik országban, 3 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 100 fő vett részt
- Kezdés
- 2023. nov. 27.
- Befejezés
- 2025. szept. 9.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Anticoagulation
- mechanical aspiration thrombectomy
- A regiszteradat frissítve
- 2026. augusztus 18.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-80 years old
- Clinical signs and symptoms consistent with acute PE with duration of 14 days or less
- Objectively confirmed acute PE, based on computed tomographic pulmonary angiography (CTPA) imaging showing a filling defect in at least one main or proximal lobar pulmonary artery
- Classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction with RV/LV ratio ≥1.0 on CTPA and elevated cardiac biomarkers, including cardiac troponin, BNP, and/or NT-pro BNP above the upper limit of normal
- Jugular or femoral access deemed suitable to accommodate pulmonary artery intervention with the Indigo Aspiration System
- Informed consent is obtained from either the patient or legally authorized representative (LAR)
Ki nem vehet részt
- Administration of thrombolytic agents or glycoprotein IIb/IIIa receptor antagonist within 30 days prior to baseline imaging
- Cardiovascular or pulmonary surgery within last 7 days
- Current participation in another investigational drug or device trial that may confound the results of this trial. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
- Hemodynamic instability with any of the following present:; Cardiac arrest; Obstructive shock or persistent hypotension defined as systolic blood pressure (BP) <90 mmHg or an acute drop in systolic BP ≥40 mmHg for >15 min, or requiring vasopressor or inotropic support to achieve a systolic BP ≥90 mmHg
- History, imaging or hemodynamic findings consistent with chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
- Allergy, hypersensitivity, or heparin induced thrombocytopenia (HIT)
- Severe active infection (e.g. sepsis) requiring treatment at time of enrollment
- Active bleeding or disorders contraindicating anticoagulant therapy
- Primary brain or metastatic brain cancer
- Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the trial, including compliance with follow-up requirements, or that could impact the scientific integrity of the trial
- <45 mL/min creatinine clearance
- Hemoglobin <10 g/dL
- Platelets <100,000/μL
- INR >3
- Patients on ECMO
- National Early Warning Score (NEWS) 2 ≥9
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, that catheter-based intervention is not appropriate for the patient
- Contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated
- Life expectancy <90 days
- Pregnancy
- Intracardiac thrombus (right atrium, right ventricle clot in transit) or thrombus in the inferior vena cava identified on baseline imaging
Helyszínek itt: Egyesült Államok
Még 3 másik országban, 3 helyszínen
- Ascension Seton Medical Center AustinAustin, Egyesült Államok
- University of MarylandBaltimore, Egyesült Államok
- McLaren Bay Heart & VascularBay City, Egyesült Államok
- Cooper Health SystemCamden, Egyesült Államok
- Northwestern MemorialChicago, Egyesült Államok
- Rush University Medical CenterChicago, Egyesült Államok
- Baylor University Medical CenterDallas, Egyesült Államok
- Joseph Maxwell Cleland Atlanta VA Medical CenterDecatur, Egyesült Államok
- St. Elizabeth Edgewood HospitalEdgewood, Egyesült Államok
- Kingwood Medical CenterKingwood, Egyesült Államok
- Radiology and Imaging Specialists/Lakeland RegionalLakeland, Egyesült Államok
- Cedars-Sinai Medical CenterLos Angeles, Egyesült Államok
- UCLA Medical CenterLos Angeles, Egyesült Államok
- Wellstar - KennestoneMarietta, Egyesült Államok
- Mount Sinai HospitalNew York, Egyesült Államok
- Sentara Norfolk General HospitalNorfolk, Egyesült Államok
- Corewell Health William Beaumont University HospitalRoyal Oak, Egyesült Államok
- Metropolitan Methodist HospitalSan Antonio, Egyesült Államok
- The University of Arizona - BannerTucson, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).
A vizsgálat 2 csoportja
- Anticoagulation (AC)Már használt kezelés, összehasonlításként
Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.
Kezelés: Anticoagulation
- IndigoMár használt kezelés, összehasonlításként
Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.
Kezelés: mechanical aspiration thrombectomy
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- STORM-PE: A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone vs Anticoagulation Plus Mechanical Aspiration With the Indigo® Aspiration System for the Treatment of Intermediate High Risk Acute Pulmonary Embolism
- Publikációk
- Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE: Improved Functional 90-Day Outcomes in STORM-PE RCT.JACC. Cardiovascular interventions, 2026
- Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial.Circulation, 2026
- A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatment of intermediate-high-risk acute pulmonary embolism: Rationale and design of the STORM-PE study.American heart journal, 2025
- A regiszteradat frissítve
- 2026. augusztus 18.